Does Rallies show 13F holders for ABEO?

Yes. Rallies tracks hedge fund and 13F ownership data for ABEO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ABEO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ABEO. It does not provide personalized investment advice.

ABEO (Abeona Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Abeona Therapeutics Inc. Common Stock (ABEO) is a publicly traded Healthcare sector company. As of May 21, 2026, ABEO trades at $5.36 with a market cap of $306.06M and a P/E ratio of -3.42. ABEO moved +4.10% today. Year to date, ABEO is +1.92%; over the trailing twelve months it is -17.13%. Its 52-week range spans $3.93 to $7.54. Analyst consensus is strong buy with an average price target of $20.67. Rallies surfaces ABEO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ABEO stock?

Hedge funds tracked by Rallies that own ABEO include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Abeona Therapeutics Inc. Common Stock.

ABEO Key Metrics

Key financial metrics for ABEO
Metric	Value
Price	$5.36
Market Cap	$306.06M
P/E Ratio	-3.42
EPS	$-1.55
Dividend Yield	0.00%
52-Week High	$7.54
52-Week Low	$3.93
Volume	5
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-63.73M
Gross Margin	0.00%

Top Hedge Funds Holding ABEO

Panagora Asset holds 199.15K shares of ABEO, changed +19.46% as of Mar 31, 2026.

Latest ABEO News

Abeona Therapeutics Reports Strong Q1 2026 Revenue Growth and Pipeline Update — May 14, 2026
Abeona’s Q1 ZEVASKYN Revenue Rises to $8.7M; Licenses $7M PSMA Therapy — May 13, 2026
Children’s Hospital of Philadelphia Joins as Sixth ZEVASKYN Treatment Center — May 11, 2026
Abeona Names Keith Goldan to Board, Veteran CFO with Two Syndax Approvals — Apr 7, 2026
Abeona Activates NewYork-Presbyterian/Columbia as Fifth ZEVASKYN Treatment Center — Apr 2, 2026

Recent ABEO Insider Trades

Crombez Eric sold 26.14K (~$144.64K) on May 15, 2026.
Vasanthavada Madhav sold 5.55K (~$33.07K) on May 11, 2026.
Seshadri Vishwas sold 29.98K (~$131.48K) on Mar 31, 2026.

ABEO Analyst Consensus

6 analysts cover ABEO: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.67.

Common questions about ABEO

Who owns ABEO stock?: Hedge funds tracked by Rallies that own ABEO include Panagora Asset. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Abeona Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for ABEO?: Yes. Rallies tracks hedge fund and 13F ownership data for ABEO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ABEO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ABEO. It does not provide personalized investment advice.